Drugs in R & D

, Volume 2, Issue 2, pp 116–117 | Cite as

PMS 812

S 21663
Section 1: Type 2 Diabete Mellitus Adis R&D Profile


Adis International Limited Piperazine Imidazoline MIN6 Cell Antidiabetic Activity 


  1. 1.
    Wang X, Rondu F, Lamouri A, et al. Effect of S-21663 (PMS 812), an imidazoline derivative, on glucose tolerance and insulin secretion in a rat model of type II diabetes. J Pharmacol Exper Ther 1996 Jul; 278: 82–9Google Scholar
  2. 2.
    Rondu F, Le Bihan G, Wang X, et al. Structure-activity relationships in a series of substituted piperazines potentially active in non-insulin-dependent diabetes mellitus [abstract]. XIIIth International Symposium of Medicinal Chemistry. 1994 Sep 19–23; Paris, 263Google Scholar
  3. 3.
    Le Brigand L, Virsolvy A, Peyrollier K, et al. Stimulation of insulin release fromthe MIN6 cell line by a newimidazoline compound, S-21663: evidence for the existence of a novel imidazoline site in beta cells. Br J Pharmacol 1997 Oct; 122: 786–91PubMedCrossRefGoogle Scholar
  4. 4.
    Le Bihan G, Rondu F, Pelé-Tounian A, et al. Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 2. Syntheses and biological activities of 1,4-dialkyl-, 1,4-dibenzyl, and 1-benzyl- 4-alkyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazines and isosteric analogues of imidazoline. J Med Chem 1999 May 6; 42: 1587–603PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Personalised recommendations